Milnacipran for the management of fibromyalgia syndrome

References

• MeasePArnoldLMBennettRFibromyalgia syndromeJ Rheumatol2007341415142517552068
   PubMed Web of Science ®Google Scholar
• GranJTThe epidemiology of chronic generalized musculoskeletal painBest Pract Res Clin Rheumatol20031754756112849711
   PubMed Web of Science ®Google Scholar
• WolfeFMichaudKSevere rheumatoid arthritis (RA), worse ourcomesm comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromylagiaJ Rheum20043169570015088293
   PubMed Web of Science ®Google Scholar
• MiddletonGDMcFarlanJELipskyPEThe prevalence and clinical impact of fibromyalgia in systemic lupus erythematosisArthritis Rheum199437118111888053957
   PubMed Web of Science ®Google Scholar
• WolfeFSmytheHAYunusMBThe American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria CommitteeArthritis Rheum1990331601722306288
   PubMed Web of Science ®Google Scholar
• WolfeFStop using the American College of Rheumatology Criteria in the ClinicJ Rheumatol2003308167116212913920
   PubMed Web of Science ®Google Scholar
• CarvilleSFArendt-NielsenSBliddalHEULAR evidence-based recommendations for the management of fibromyalgia syndromeAnn Rheum Dis20086753654117644548
   PubMed Web of Science ®Google Scholar
• WolfeFClauwDFitzcharlesMAClinical Diagnostic and Severity Criteria for FibromyalgiaArthitis Rheum20096010 supplementS210Presented at the 2009 ACR/ARHP Scientific MeetingSunday October 18, 2009
   Google Scholar
• BoomershineCSCroffordLJA symptom-based approach to pharmacologic management of fibromyalgiaNat Rev Rheumatol2009519119919337283
   PubMed Web of Science ®Google Scholar
• BennettRMFriendRJonesKDThe Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric propertiesArthritis Res Ther2009114R120 Available at http://arthritis-research.com/content/11/4/R120.19664287
   PubMed Web of Science ®Google Scholar
• AbelesAMPillingerMHSolitarBMAbelesMNarrative review: The pathophysiology of fibromyalgiaAnn Intern Med200714672673417502633
   PubMed Web of Science ®Google Scholar
• GracelyRHPetzkeFWolfJMClauwDJFunctional magnetic resonance inaging evidence of augmented pain processing in fibromyalgiaArthritis Rheum2002461333134312115241
   PubMed Web of Science ®Google Scholar
• GieseckeTGracelyRHWilliamsDAThe relationship between depression, clinical pain, and experimental pain in a chronic pain chortArthritis Rheum2005521577158415880832
   PubMed Web of Science ®Google Scholar
• CookDBLangeGCicconeDSFunctional imaging of pain in patients with primary fibromyalgiaJ Rheumatol20043136437814760810
   PubMed Web of Science ®Google Scholar
• DubnerRHargreavesKMThe neurobiology of pain and its modulationClin J Pain19895Suppl 2S1S42520436
   PubMed Web of Science ®Google Scholar
• RussellIJVaeroyHJavorsMNybergFCerebrospinal fluid biogenic anime metabolites in fibromyalgia/ fibrositis syndrome and rheumatoid arthritisArthritis Rheum1992355505561374252
   PubMed Web of Science ®Google Scholar
• Van KoulilSEffingMKraaimaatFWvan LankveldWvan HelmondTCatsHCognitive-behavioral therapies and exercise programmes for patients with fibromyalgia: state of the art and future directionsAnn Rheum Dis20076657158116916856
   PubMed Web of Science ®Google Scholar
• GoldenbergDLBurckhardtCCroffordLManagement of fibromyalgia syndromeJAMA200429223889515547167
   PubMed Web of Science ®Google Scholar
• ObataHSaitoSKoizukaSThe monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic painAnesth Analg20051001306141015845674
   PubMed Web of Science ®Google Scholar
• VaishnaviSNNemeroffCBPlottSJMilnacipran: A comparative analysis of human monoamine uptake and transporter binding affinityBiol Psychiatry20045532032214744476
   PubMed Web of Science ®Google Scholar
• LeoRBrooksVLClinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in painCurr Opin Investig Drugs20067637642
   Google Scholar
• ScholtzBAHammondsCLBoomershineCSDuloxetine for the management of fibromyalgia syndromeJ Pain Res2009299108
   Google Scholar
• VaishnaviSNNemeroffCBPlottSJRaoSGKranzlerJOwensMJMilnacipran: a comparative analysis of human monoamine uptake and transporter binding affinityBiol Psychiatry20045532032214744476
   PubMed Web of Science ®Google Scholar
• TurcotteJEDebonnelGde MontignyCHebertCBlierPAssessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjectsNeuropsychopharmacology20012451152111282251
   PubMed Web of Science ®Google Scholar
• PuozzoCLensSRehCLack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressantsClin Pharmacokinet20054497798816122284
   PubMed Web of Science ®Google Scholar
• WestanmoADGaykenJHaightRDuloxetine: a balanced and selective norepinephrineand serotonin-reuptake inhibitorAm J Health Syst Pharm2005622481249016303903
   PubMed Web of Science ®Google Scholar
• PuozzoCAlbinHVinconGDeprezDRaymondJMAmourettiMPharmacokinetics of milnacipan in liver impairmentEur J Drug Metab Pharmacokinet1998232732799725493
   PubMed Web of Science ®Google Scholar
• http://pi.lilly.com/us/cymbalta-pi.pdf. Accessed November 4, 2009.
   Google Scholar
• PuozzoCPozetNDeprezDBaillePUngHLZechPPharmacokinetics of milnacipran in renal impairmentEur J Drug Metab Pharmacokinet19982328069725494
   PubMed Web of Science ®Google Scholar
• http://www.frx.com/pi/Savella_pi.pdf. accessed November 4, 2009.
   Google Scholar
• GahimerJWernickeJYalcinIA retrospective pooled analysis of duloxetine safety in 23,983 subjectsCurr Med Res Opin20072317518417257478
   PubMed Web of Science ®Google Scholar
• ClauwDJPharmacotherapy for patients with fibromyalgiaJ Clin Psychiatry200869suppl 2252918537460
   PubMedGoogle Scholar
• MeasePJClauwDJGendreauRMThe efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trialJ Rheumatol20093639840919132781
   PubMed Web of Science ®Google Scholar
• VittonOGendreauMGendreauJKranzlerJRaoSGA double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgiaHum Psychopharmacol200419Suppl 1S27S3515378666
   PubMed Web of Science ®Google Scholar
• GendreauRMThornMDGendreauJFKranzlerJDEfficacy of milnacipran in patients with fibromyalgiaJ Rheumatol2005321975198516206355
   PubMed Web of Science ®Google Scholar
• ClauwDJMeasePPalmerRHGendreauRMWangYMilnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trialClin Ther2008301988200419108787
   PubMed Web of Science ®Google Scholar
• StoneAAShiffmanSSchwartzJEBroderickJEHuffordMRPatient non-compliance with paper diariesBMJ20023241193119412016186
   PubMed Web of Science ®Google Scholar
• GracelyRHKwiloszDMThe descriptor differential scale: applying psychophysical principles to clinical pain assessmentPain1988352792883226757
   PubMed Web of Science ®Google Scholar
• BurckhardtCSClarkSRBennettRMThe fibromyalgia impact questionnaire: development and validationJ Rheumatol1991187287331865419
   PubMed Web of Science ®Google Scholar
• WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care1992304734831593914
   PubMed Web of Science ®Google Scholar
• BeckATWardCHMendelsonMAn inventory for measuring depressionArch Gen Psychiatry1961456157113688369
   PubMed Web of Science ®Google Scholar
• JenkinsCDStantonBANiemcrykSJA scale for the estimation of sleep problems in clinical researchJ Clin Epidemiol1988413133213351539
   PubMed Web of Science ®Google Scholar
• McGahueyCAGelenbergAJLaukesCAThe Arizona Sexual Experience Scale (ASEX): reliability and validityJ Sex Marital Ther200026254010693114
   PubMed Web of Science ®Google Scholar
• DworkinRHKatzJGitlinMJPlacebo response in clinical trials of depression and its implications for research on chronic neuropathic painNeurology200565Suppl 4S7S1916385107
   PubMed Web of Science ®Google Scholar
• GoldenbergDClauwDJPalmerRHOne-year durability of response to milnacipran treatment for fibromyalgiaArthritis Rheum200756Suppl 9S603
   Google Scholar
• ArnoldLMRosenAPritchettYLA randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorderPain200511951516298061
   PubMed Web of Science ®Google Scholar
• RussellIJMeasePJSmithTREfficacy and safety of duloxetine for the treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed dose trialPain200813643244418395345
   PubMed Web of Science ®Google Scholar
• ArnoldLMRussellIJDiriEWA 14-week, randomized, double-blinded placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgiaJ Pain2008979280518524684
   PubMed Web of Science ®Google Scholar
• MeasePJRussellIJArnoldLMA randomized, double-blinded, placebo-controlled, phase III trial of pregabalin in treatment of patients with fibromyalgiaJ Rheumatol20083550251418278830
   PubMed Web of Science ®Google Scholar
• LecrubierYPletanYSollesATournouxAMagneVClinical efficacy of milnacipran: placebo-controlled trialsInt Clin Psychopharm199611Suppl 42933
   PubMed Web of Science ®Google Scholar
• KasperSPleatanYSollesATournouxAComparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial resultsInt Clin Psychopharm199611Suppl 43539
   PubMed Web of Science ®Google Scholar
• NakagawaAWatanabeNOmoriIMMilnacipran versus other antidepressive agents for depressionCochrane Database Syst Rev20093CD00652919588396
   PubMed Web of Science ®Google Scholar